Regulatory T cells and NK cells in cancer patients;Regulatorische T-Zellen und NK-Zellen bei Krebspatienten

HNO

Volumn 62, Issue 6, 2014, Pages 406-414

  Bergmann, C ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Head and neck cancer; Immune response; Immunologic cytotoxicity; Immunology; Tumor escape

Indexed keywords

BIOLOGICAL MODEL; CELL COMMUNICATION; HEAD AND NECK TUMOR; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; NATURAL KILLER CELL; PATHOLOGY; REGULATORY T LYMPHOCYTE;

CELL COMMUNICATION; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES, REGULATORY;

EID: 84902332123     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-014-2874-9     Document Type: Article

References (53)

1. Knudson AG Jr (1985) Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 45: 1437-1443.
2. Ehrlich P (1907) Experimentelle Studien an Mäusetumoren. Z Krebsforsch 5: 59-81.
3. Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6: 836-848.
4. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480: 480-489.
5. Roncarolo MG, Gregori S, Battaglia M et al (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212: 28-50.
6. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
7. Liu W, Putnam AL, Xu-Yu Z et al (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203: 1701-1711.
8. Strauss L, Bergmann C, Szczepanski M et al (2007) A unique subset of CD4+ CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13: 4345-4354.
9. Bergmann C, Strauss L, Zeidler R et al (2007) Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol Immunother 56: 1429-1442.
10. Groux H (2003) Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation 75: 8S-12S.
11. Curotto de Lafaille MA, Lafaille JJ (2009) Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30: 626-635.
12. Bergmann C, Strauss L, Wang Y et al (2008) T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14: 3706-3715.
13. Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
14. Dranoff G (2005) The therapeutic implications of intratumoral regulatory T cells. Clin Cancer Res 11: 8226-8229.
15. Whiteside TL (2014) Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 63: 67-72.
16. Trinchieri G (1995) Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin Immunol 7: 83-88.
17. Screpanti V, Wallin RP, Grandien A et al (2005) Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 42: 495-499.
18. Kärre K (1985) Role of target histocompatibility antigens in regulation of natural killer activity. a reevaluation and a hypothesis. Academic Press, Orlando/FL, USA.
19. Moretta L, Moretta A (2004) Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 23: 255-259.
20. Biassoni R, Cantoni C, Marras D et al (2003) Human natural killer cell receptors: insights into their molecular function and structure. J Cell Mol Med 7: 376-387.
21. Wu JD, Higgins LM, Steinle A et al (2004) Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114: 560-568.
22. Whiteside TL (2009) Tricks tumors use to escape from immune control. Oral Oncol 45: e119-e123.
23. Wild CA, Brandau S, Lotfi R et al (2012) HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol 48: 409-416.
24. Ghiringhelli F, Menard C, Terme M et al (2005) CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202: 1075-1085.
25. Smyth MJ, Teng MW, Swann J et al (2006) CD4+ CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 176: 1582-1587.
26. Battaglia M, Stabilini A, Migliavacca B et al (2006) Rapamycin promotes expansion of functional CD4+ CD25+ FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 177: 8338-8347.
27. Groux H, O'Garra A, Bigler M et al (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737-742.
28. Astier AL, Meiffren G, Freeman S et al (2006) Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest 116: 3252-3257.
29. Raulet DH (2003) Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3: 781-790.
30. Raulet DH, Guerra N (2009) Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 9: 568-580.
31. Zhou H, Chen L, You Y et al (2010) Foxp3-transduced polyclonal regulatory T cells suppress NK cell functions in a TGF-beta dependent manner. Autoimmunity 43: 299-307.
32. Meadows SK, Eriksson M, Barber A et al (2006) Human NK cell IFN-gamma production is regulated by endogenous TGF-beta. Int Immunopharmacol 6: 1020-1028.
33. Bergmann C, Strauss L, Zeidler R et al (2007) Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 67: 8865-8873.
34. Frimpong-Boateng K, Rooijen N van, Geiben-Lynn R (2010) Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGFbeta. PLoS One 5: e12281.
35. Giroux M, Yurchenko E, St-Pierre J et al (2007) T regulatory cells control numbers of NK cells and CD8alpha+ immature dendritic cells in the lymph node paracortex. J Immunol 179: 4492-4502.
36. Ralainirina N, Poli A, Michel T et al (2007) Control of NK cell functions by CD4+ CD25+ regulatory T cells. J Leukoc Biol 81: 144-153.
37. Barao I, Hanash AM, Hallett W et al (2006) Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A 103: 5460-5465.
38. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218.
39. Herberman RB (2002) Cancer immunotherapy with natural killer cells. Semin Oncol 29: 27-30.
40. Badoual C, Hans S, Rodriguez J et al (2006) Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12: 465-472.
41. Carreras J, Lopez-Guillermo A, Fox BC et al (2006) High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108: 2957-2964.
42. Alvaro T, Lejeune M, Salvado MT et al (2005) Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11: 1467-1473.
43. Correale P, Rotundo MS, Del Vecchio MT et al (2010) Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 33: 435-441.
44. Salama P, Phillips M, Grieu F et al (2009) Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27: 186-192.
45. Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127: 759-767.
46. Dannull J, Su Z, Rizzieri D et al (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115: 3623-3633.
47. Berntsen A, Brimnes MK, thor Straten P et al (2010) Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J Immunother 33: 425-434.
48. Jacobs JF, Punt CJ, Lesterhuis WJ et al (2010) Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res 16:5067-5078
49. Zimmer J, Andres E, Hentges F (2008) NK cells and Treg cells: a fascinating dance cheek to cheek. Eur J Immunol 38: 2942-2945.
50. Bauer S, Groh V, Wu J et al (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729.
51. Cao X, Cai SF, Fehniger TA et al (2007) Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27: 635-646.
52. Vacca P, Cantoni C, Vitale M et al (2010) Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression. Proc Natl Acad Sci U S A 107: 11918-11923.
53. Bergmann C, Wild CA, Narwan M et al (2011) Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells. Eur J Immunol 41: 3564-3573.